146 related articles for article (PubMed ID: 29953021)
1. Side effects and medication adherence of tyrosine kinase inhibitors for patients with chronic myeloid leukemia in Taiwan.
Tsai YF; Huang WC; Cho SF; Hsiao HH; Liu YC; Lin SF; Liu TC; Chang CS
Medicine (Baltimore); 2018 Jun; 97(26):e11322. PubMed ID: 29953021
[TBL] [Abstract][Full Text] [Related]
2. Disease acceptance and adherence to imatinib in Taiwanese chronic myeloid leukaemia outpatients.
Chen LC; Chen TC; Huang YB; Chang CS
Int J Clin Pharm; 2014 Feb; 36(1):120-7. PubMed ID: 24154825
[TBL] [Abstract][Full Text] [Related]
3. Comprehensive Evaluation of Adherence to Therapy, Its Associations, and Its Implications in Patients With Chronic Myeloid Leukemia Receiving Imatinib.
Unnikrishnan R; Veeraiah S; Mani S; Rajendranath R; Rajaraman S; Vidhubala Elangovan GS; Radhakrishnan V; Ganesan TS; Sagar TG; Ganesan P
Clin Lymphoma Myeloma Leuk; 2016 Jun; 16(6):366-371.e3. PubMed ID: 27052853
[TBL] [Abstract][Full Text] [Related]
4. Factors influencing adherence in CML and ways to improvement: Results of a patient-driven survey of 2546 patients in 63 countries.
Geissler J; Sharf G; Bombaci F; Daban M; De Jong J; Gavin T; Pelouchova J; Dziwinski E; Hasford J; Hoffmann VS
J Cancer Res Clin Oncol; 2017 Jul; 143(7):1167-1176. PubMed ID: 28289895
[TBL] [Abstract][Full Text] [Related]
5. Adherence to tyrosine kinase inhibitor therapy for chronic myeloid leukemia: a Brazilian single-center cohort.
de Almeida MH; Pagnano KB; Vigorito AC; Lorand-Metze I; de Souza CA
Acta Haematol; 2013; 130(1):16-22. PubMed ID: 23363706
[TBL] [Abstract][Full Text] [Related]
6. Association between regular molecular monitoring and tyrosine kinase inhibitor therapy adherence in chronic myelogenous leukemia in the chronic phase.
Guérin A; Chen L; Dea K; Wu EQ; Goldberg SL
Curr Med Res Opin; 2014 Jul; 30(7):1345-52. PubMed ID: 24640967
[TBL] [Abstract][Full Text] [Related]
7. Medication Adherence to Tyrosine Kinase Inhibitors: 2-Year Analysis of Medication Adherence to Imatinib Treatment for Chronic Myeloid Leukemia and Correlation with the Depth of Molecular Response.
Santoleri F; Lasala R; Ranucci E; La Barba G; Di Lorenzo R; Vetrò A; Di Bartolomeo P; Costantini A
Acta Haematol; 2016; 136(1):45-51. PubMed ID: 27160310
[TBL] [Abstract][Full Text] [Related]
8. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.
Steinberg M
Clin Ther; 2007 Nov; 29(11):2289-308. PubMed ID: 18158072
[TBL] [Abstract][Full Text] [Related]
9. Factors Associated With Tyrosine Kinase Inhibitor Initiation and Adherence Among Medicare Beneficiaries With Chronic Myeloid Leukemia.
Winn AN; Keating NL; Dusetzina SB
J Clin Oncol; 2016 Dec; 34(36):4323-4328. PubMed ID: 27998234
[TBL] [Abstract][Full Text] [Related]
10. Is Adherence to Imatinib Mesylate Treatment Among Patients with Chronic Myeloid Leukemia Associated with Better Clinical Outcomes in Qatar?
Al-Dewik NI; Morsi HM; Samara MM; Ghasoub RS; Gnanam CC; Bhaskaran SK; Nashwan AJ; Al-Jurf RM; Ismail MA; AlSharshani MM; AlSayab AA; Ben-Omran TI; Khatib RB; Yassin MA
Clin Med Insights Oncol; 2016; 10():95-104. PubMed ID: 27721664
[TBL] [Abstract][Full Text] [Related]
11. Good adherence to imatinib therapy among patients with chronic myeloid leukemia--a single-center observational study.
Jönsson S; Olsson B; Söderberg J; Wadenvik H
Ann Hematol; 2012 May; 91(5):679-685. PubMed ID: 22048790
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of a medication management service in improving adherence to tyrosine kinase inhibitors and clinical outcomes of patients with chronic myeloid leukaemia: a randomised controlled trial.
Tan BK; Chua SS; Chen LC; Chang KM; Balashanker S; Bee PC
Support Care Cancer; 2020 Jul; 28(7):3237-3247. PubMed ID: 31734798
[TBL] [Abstract][Full Text] [Related]
13. Impact of oncology pharmacist-managed oral anticancer therapy in patients with chronic myelogenous leukemia.
Lam MS; Cheung N
J Oncol Pharm Pract; 2016 Dec; 22(6):741-748. PubMed ID: 26419691
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of Medication Adherence and Pharmacokinetics of Dasatinib for Earlier Molecular Response in Japanese Patients With Newly Diagnosed Chronic Myeloid Leukemia: A Pilot Study.
Iwamoto T; Monma F; Ohishi K; Umino A; Suzuki K; Oka K; Kawakami K; Sekine T; Okuda M; Katayama N
Ther Drug Monit; 2019 Oct; 41(5):575-581. PubMed ID: 31008998
[TBL] [Abstract][Full Text] [Related]
15. Initiation of generic imatinib may improve medication adherence for patients with chronic myeloid leukemia.
Cole AL; Jazowski SA; Dusetzina SB
Pharmacoepidemiol Drug Saf; 2019 Nov; 28(11):1529-1533. PubMed ID: 31507005
[TBL] [Abstract][Full Text] [Related]
16. Treatment adherence in chronic myeloid leukaemia patients receiving tyrosine kinase inhibitors.
Rychter A; Jerzmanowski P; Hołub A; Specht-Szwoch Z; Kalinowska V; Tęgowska U; Seferyńska I; Kołkowska-Leśniak A; Lech-Marańda E; Góra-Tybor J
Med Oncol; 2017 Jun; 34(6):104. PubMed ID: 28444623
[TBL] [Abstract][Full Text] [Related]
17. Adherence and Coping Strategies in Outpatients With Chronic Myeloid Leukemia Receiving Oral Tyrosine Kinase Inhibitors.
Hefner J; Csef EJ; Kunzmann V
Oncol Nurs Forum; 2017 Nov; 44(6):E232-E240. PubMed ID: 29052661
[TBL] [Abstract][Full Text] [Related]
18. Effect of Adherence-enhancing Interventions on Adherence to Tyrosine Kinase Inhibitor Treatment in Chronic Myeloid Leukemia (TAKE-IT): A Quasi-experimental Pre-Post Intervention Multicenter Pilot Study.
Leader A; Benyamini N; Gafter-Gvili A; Dreyer J; Calvarysky B; Amitai A; Yarchovsky-Dolberg O; Sharf G; Tousset E; Caspi O; Ellis M; Levi I; De Geest S; Raanani P
Clin Lymphoma Myeloma Leuk; 2018 Nov; 18(11):e449-e461. PubMed ID: 30030034
[TBL] [Abstract][Full Text] [Related]
19. Cost sharing and adherence to tyrosine kinase inhibitors for patients with chronic myeloid leukemia.
Dusetzina SB; Winn AN; Abel GA; Huskamp HA; Keating NL
J Clin Oncol; 2014 Feb; 32(4):306-11. PubMed ID: 24366936
[TBL] [Abstract][Full Text] [Related]
20. Adherence to tyrosine kinase inhibitors among Medicare Part D beneficiaries with chronic myeloid leukemia.
Shen C; Zhao B; Liu L; Shih YT
Cancer; 2018 Jan; 124(2):364-373. PubMed ID: 28976559
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
